321 528

Cited 12 times in

Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation-Positive Lung Adenocarcinoma

DC Field Value Language
dc.contributor.author장윤수-
dc.contributor.author차윤진-
dc.date.accessioned2020-02-26T06:43:00Z-
dc.date.available2020-02-26T06:43:00Z-
dc.date.issued2020-
dc.identifier.issn1738-3536-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/175262-
dc.description.abstractBACKGROUND: Programmed death-ligand 1 (PD-L1) expression is tested by immunohistochemistry (IHC)-22C3, SP263, and SP142. The aim of this study is to evaluate the correlation among the three methods of PD-L1 IHC in non-small cell lung cancer (NSCLC) and clinical significance of PD-L1 expression in lung adenocarcinoma with an epidermal growth factor receptor (EGFR)-tyrosine kinase domain mutation. METHODS: The results of 230 patients who were pathologically confirmed as having NSCLC; tested using PD-L1 IHC 22C3, SP263, and SP142 methods; and evaluated via the peptide nucleic acid clamping method to confirm EGFR mutation, were analyzed in this study. RESULTS: 164 patients underwent both the SP263 and 22C3 tests. There was a significant positive correlation between the outcomes of the two tests (Spearman correlation coefficient=0.912, p<0.001), with a derived regression equation as follows: 22C3=15.2+0.884×SP263 (R²=0.792, p<0.001). There was no relationship between the expression of PD-L1 and clinical parameters, including EGFR-tyrosine kinase inhibitor (TKI) mutation. The PD-L1 expression in patients treated with EGFR-TKI yielded a 2-month-shorter progression period than that in the PD-L1-negative group. However, this did not reach statistical significance (PD-L1<1% vs. PD-L1≥1%, 10 months vs. 8 months). CONCLUSION: The results of the 22C3 and those of SP263 methods were in good correlation with one another. Since the PD-L1 expression is not influenced by the EGFR mutation, it is necessary to perform a PD-L1 test to set the treatment direction in the patients with EGFR-mutant NSCLC.-
dc.description.statementOfResponsibilityopen-
dc.languageKorean-
dc.publisher대한결핵 및 호흡기학회-
dc.relation.isPartOfTUBERCULOSIS AND RESPIRATORY DISEASES-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleCorrelation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation-Positive Lung Adenocarcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorTaehee Kim-
dc.contributor.googleauthorYoon Jin Cha-
dc.contributor.googleauthorYoon Soo Chang-
dc.identifier.doi10.4046/trd.2019.0026-
dc.contributor.localIdA03456-
dc.contributor.localIdA04001-
dc.relation.journalcodeJ02761-
dc.identifier.eissn2005-6184-
dc.identifier.pmid31905432-
dc.subject.keywordCompanion Diagnotics-
dc.subject.keywordEGFR-
dc.subject.keywordNon-Small Cell Lung Cancer-
dc.subject.keywordPD-L1-
dc.contributor.alternativeNameChang, Yoon Soo-
dc.contributor.affiliatedAuthor장윤수-
dc.contributor.affiliatedAuthor차윤진-
dc.citation.volume83-
dc.citation.number1-
dc.citation.startPage51-
dc.citation.endPage60-
dc.identifier.bibliographicCitationTUBERCULOSIS AND RESPIRATORY DISEASES, Vol.83(1) : 51-60, 2020-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.